SAN DIEGO, July 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit.  Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with vi ...

Core Viewpoint - The article discusses a class action lawsuit against Tempus AI, Inc. due to allegations of misleading statements and inflated financial metrics during a specified class period, leading to significant stock price decline [1][2][4]. Summary by Relevant Sections Class Action Details - Investors who purchased Tempus common stock between August 6, 2024, and May 27, 2025, are reminded of the August 12, 2025, deadline to file a lead plaintiff motion [1][5]. - The lawsuit claims that the defendants made materially false and misleading statements about the company's business and operations [4]. Allegations Against Tempus - A report by Spruce Point Capital on May 28, 2025, alleged that Tempus overstated its AI capabilities and revealed weaknesses in its financial guidance [2]. - Following this report, Tempus' stock price dropped by $12.67, or 19.2%, closing at $53.20 per share [3]. Specific Misconduct Allegations - The complaint outlines several key issues: 1. Inflated value of contract agreements, including non-binding opt-ins and self-funded contracts [4]. 2. Risk to the credibility of a joint venture with SoftBank, suggesting potential "round-tripping" of capital [4]. 3. Ambry's business model involved aggressive billing practices that could face scrutiny [4]. 4. AstraZeneca's reduced financial commitments through a questionable payment structure [4]. 5. Overall, these issues indicated weaknesses in Tempus' core operations and revenue prospects [4].

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top ...

Core Insights - Tempus AI (TEM) is advancing precision medicine through a strong pipeline of R&D initiatives, including the introduction of xM, a liquid biopsy assay for advanced solid tumors, and the launch of the Fuses program to enhance AI-enabled diagnostics [1][2][3] Product Development - The company launched olivia, an AI-enabled personal health concierge app, and an FDA-approved NGS-based in vitro diagnostic device, xT CDx, for solid tumor profiling [2] - Tempus AI is developing its first whole-genome sequencing test, xH, aimed at supporting personalized therapy in hematological oncology [3] Competitive Landscape - Peers like Veracyte (VCYT) and Myriad Genetics (MYGN) are also innovating in precision diagnostics, with Veracyte launching the Decipher Prostate test and Myriad introducing the Prequel Prenatal Screen and Foresight Carrier Screening test [4][5] Financial Performance - Over the past year, Tempus AI shares have increased by 83.6%, outperforming the industry growth of 38% and the S&P 500's 12.3% [6] - The company's current forward Price-to-Sales (P/S) ratio is 7.50X, higher than the industry average of 5.88X [8] Earnings Estimates - Earnings estimates for Tempus AI show a mixed outlook for 2025 and 2026, with current estimates remaining stable over the past month [10][11]

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for alleged violations of securities laws, specifically for making false and misleading statements regarding its financial agreements and business practices [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Tempus exaggerated the value of several agreements, including transactions with affiliated entities and internally financed deals [2]. - Concerns have been raised about a joint venture with SoftBank, which may be perceived as "round-tripping" funds to inflate revenue [2]. - The acquisition of Ambry by Tempus is highlighted, noting Ambry's reputation for aggressive and potentially unethical business conduct, which further undermines the credibility of Tempus's public statements [2]. Group 2: Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through balanced counseling and aggressive advocacy [3]. - The firm represents some of the largest hedge funds and alternative asset managers, indicating a strong focus on high-value litigation claims [3].

Core Viewpoint - The market's interest in artificial intelligence stocks, particularly Tempus AI, remains strong, with significant stock price increases observed over recent months [1][5]. Stock Performance - Tempus AI shares rose 7.1% in April, 6.8% in May, and 15.2% in June, indicating a robust upward trend [1][5]. - The stock closed at $55.18 on the last trading day of May, with price targets raised by analysts from Bank of America and Guggenheim to $70 and $75, respectively [5]. Analyst Sentiment - Following a critical report by Spruce Point Capital Management, initial investor panic subsided when TD Cowen dismissed the report's concerns as misleading or incorrect [4]. - Positive analyst opinions and the introduction of the Fuses program, aimed at enhancing individualized patient care, have contributed to investor confidence [2][4]. Industry Outlook - The use of AI in healthcare is still in its early stages, suggesting significant growth potential in the coming years [6]. - Despite potential volatility, the long-term prospects for Tempus AI stock appear promising, making it an attractive option for investors with a longer investment horizon [7].

Core Insights - Tempus AI is experiencing strong operational momentum with significant revenue and gross profit growth, transitioning from a high-growth startup to a scalable enterprise AI and diagnostics company [1][2] Revenue and Profit Growth - In Q4 2024, Tempus AI reported a 35.8% year-over-year revenue growth and a 49.7% increase in gross profit, primarily driven by its high-margin Data and Services segment [2] - For Q1 2025, revenues grew by 34% and gross profit increased by 45%, with gross margin rising from 42.5% to 44.5% [2][7] - The improvements were attributed to lab efficiencies, increased adoption of AI tools like Tempus One and xM, and a higher mix of data services [2][7] Future Earnings Expectations - The upcoming Q2 2025 earnings release is anticipated to show further margin expansion and sequential gains in adjusted EBITDA, supported by new offerings such as Tempus One in EHR systems and the xM liquid biopsy assay [3] - Any upward revision to guidance or increase in contract value, especially from large enterprise deals, could enhance the momentum observed in early 2025 [3] Competitive Landscape - Tempus AI's peers, such as Guardant Health and Natera, are also making significant advancements in AI-driven diagnostics, with Guardant Health introducing new assays and Natera expanding its market reach [6][8] - Natera reported a 36.5% revenue growth in Q1 2025, with gross margin expansion to 63.1%, indicating a competitive environment in personalized oncology [8] Earnings Estimates - The Zacks Consensus Estimate for Tempus AI's 2025 earnings suggests a 56.3% year-over-year improvement [9] - Current estimates indicate a potential for significant growth in earnings per share, with a year-over-year growth estimate of 63.49% for the current quarter [10] Valuation Metrics - Tempus AI currently trades at a forward Price-to-Sales (P/S) ratio of 7.52X, which is higher than the industry average of 5.8X, indicating a potentially expensive valuation [11]

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank Group was compromised, creating an appearance of "round-tripping" capital to generate revenue [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca's financial commitments to Tempus AI were reportedly reduced through a questionable "pass-through payment" arrangement, raising concerns about the company's revenue prospects [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue potential [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report from Spruce Point Capital Management raised significant concerns regarding Tempus AI's management and financial reporting, resulting in a stock price drop of over 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to serve as lead plaintiff to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].

BENSALEM, Pa., July 2, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 12, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howard G ...

Core Insights - Tempus AI, Inc. (TEM) is experiencing significant revenue growth, with a 75.4% year-over-year increase in total revenues in Q1 2025, driven by a remarkable 89% growth in Genomics revenues and a 43% rise in Data & Services revenues [1][9]. Group 1: Revenue Growth - The Genomics segment saw a 20% volume growth in oncology tests and higher average revenue per test due to increased Medicare reimbursement rates. Hereditary testing contributed $63.5 million in revenues with a 23% volume growth following the acquisition of Ambry Genetics [2]. - The Data & Services segment's growth was fueled by a 58% improvement in Insights, the data licensing business, which expanded through partnerships with major companies like Novartis, Merck EMD, Takeda, and United Therapeutics [2]. Group 2: Strategic Developments - Tempus AI signed a $200 million data and modeling license agreement with AstraZeneca and Pathos to develop the world's largest foundation model. The company is also set to launch a new liquid biopsy assay, xM, for treatment response monitoring in the coming months, along with its first whole-genome sequencing test, Xh, expected to launch next year [3]. Group 3: Competitor Performance - Exact Sciences Corporation (EXAS) reported a 10.9% revenue increase in Q1 2025, driven by strong adoption of its Cologuard product and the launch of Cologuard Plus. Precision Oncology revenues grew by 4% due to the continued adoption of Oncotype DX and the launch of Oncodetect [4]. - Exelixis (EXEL) experienced a 30.6% year-over-year revenue growth in Q1 2025, primarily due to the success of its Cabozantinib franchise, particularly the launch of CABOMETYX for advanced neuroendocrine tumors [5]. Group 4: Stock Performance and Valuation - Over the past year, Tempus AI shares have surged by 79.1%, outperforming the industry growth of 39.9% and the S&P 500's 13% improvement [6]. - Currently, TEM trades at a forward 12-month Price-to-Sales (P/S) ratio of 7.85X, compared to the industry average of 5.91X [7].